ArticleFrontiers in neurology2026
Levodopa exacerbated tremor in Parkinson's disease.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Levodopa is considered the most effective pharmacological therapy for Parkinson's disease (PD). However, it can cause side effects including diverse types of dyskinesia. In rare cases, tremor worsening has been reported in patients with PD taking levodopa. The frequency of this effect in clinical practice is unclear, and the phenomenology is poorly characterized. Objectives: We aimed to assess the frequency, clinical features, and factors associated with tremor exacerbated by levodopa in patients with PD. Methods: We studied a cohort of 274 consecutive patients with PD and determined the frequency of tremor exacerbated by levodopa. Results: Tremor exacerbation with levodopa was identified in four patients (1.46%) and 1.55% of patients taking levodopa. There were two men and two women, with ages ranging from 53 to 73 years at the time of evaluation. All patients experienced a consistent worsening of rest tremor within 20 min of taking a low dose of levodopa (62.5 mg or 125 mg). No benefit from biperiden or amantadine was observed for levodopa-exacerbated tremor in any of the cases. None of the patients showed signs of atypical parkinsonism or abnormal MRI. Patients with levodopa-exacerbated tremor were very reluctant to take more than a small dose of levodopa or any dose at all, hampering potential benefits for other parkinsonian features such as rigidity, bradykinesia, and parkinsonian gait. Conclusion: Tremor exacerbated by levodopa is an uncommon side effect in patients with PD that limits the benefit of this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.